Literature DB >> 28565914

Human melanoma inhibitory protein binds to the FN12-14 Hep II domain of fibronectin.

King Tuo Yip1, Xueyin Zhong1, Nadia Seibel1, Oliver Arnolds1, Miriam Schöpel1, Raphael Stoll1.   

Abstract

The heparin binding site (Hep II) of fibronectin plays a major role in tumor cell metastasis. Its interaction with heparan sulfate proteoglycans occurs in a variety of physiological processes including focal adhesion and migration. The melanoma inhibitory activity (MIA) is an important protein that is functionally involved in melanoma development, progression, and tumor cell invasion. After its secretion by malignant melanoma cells, MIA interacts with fibronectin and thereby actively facilitates focal cell detachment from surrounding structures and strongly promotes tumor cell invasion and the formation of metastases. In this report, the authors have determined the molecular basis of the interaction of MIA with the Hep II domain of fibronectin based on nuclear magnetic resonance spectroscopic binding assays. The authors have identified the type III modules 12 to 14 of fibronectin's Hep II as the major MIA binding sites. These results now provide a new target protein-protein binding interface for the discovery of novel antimetastatic agents against malignant melanoma in the future.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28565914      PMCID: PMC5451317          DOI: 10.1116/1.4984008

Source DB:  PubMed          Journal:  Biointerphases        ISSN: 1559-4106            Impact factor:   2.456


  56 in total

Review 1.  Mapping protein-protein interactions in solution by NMR spectroscopy.

Authors:  Erik R P Zuiderweg
Journal:  Biochemistry       Date:  2002-01-08       Impact factor: 3.162

2.  A 'rule of three' for fragment-based lead discovery?

Authors:  Miles Congreve; Robin Carr; Chris Murray; Harren Jhoti
Journal:  Drug Discov Today       Date:  2003-10-01       Impact factor: 7.851

Review 3.  Fibronectin at a glance.

Authors:  Roumen Pankov; Kenneth M Yamada
Journal:  J Cell Sci       Date:  2002-10-15       Impact factor: 5.285

4.  Combined chemical shift changes and amino acid specific chemical shift mapping of protein-protein interactions.

Authors:  Frank H Schumann; Hubert Riepl; Till Maurer; Wolfram Gronwald; Klaus-Peter Neidig; Hans Robert Kalbitzer
Journal:  J Biomol NMR       Date:  2007-10-23       Impact factor: 2.835

5.  Sequence-specific 1H, 13C, and 15N assignment of the human melanoma inhibitory activity (MIA) protein.

Authors:  R Stoll; C Renner; D Ambrosius; M Golob; W Voelter; R Buettner; A K Bosserhoff; T A Holak
Journal:  J Biomol NMR       Date:  2000-05       Impact factor: 2.835

6.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

7.  Detailed analysis of MIA protein by mutagenesis.

Authors:  Raphael Stoll; Sibylla Lodermeyer; Anja-Katrin Bosserhoff
Journal:  Biol Chem       Date:  2006-12       Impact factor: 3.915

8.  Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins.

Authors:  J C Lougheed; J M Holton; T Alber; J F Bazan; T M Handel
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-01       Impact factor: 11.205

9.  NMR 15N relaxation of the insulin-like growth factor (IGF)-binding domain of IGF binding protein-5 (IGFBP-5) determined free in solution and in complex with IGF-II.

Authors:  C Renner; T Holak
Journal:  Eur J Biochem       Date:  2001-02

10.  A unified conformational selection and induced fit approach to protein-peptide docking.

Authors:  Mikael Trellet; Adrien S J Melquiond; Alexandre M J J Bonvin
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more
  1 in total

1.  Estimation of a stronger heparin binding locus in fibronectin domain III14 using thermodynamics and molecular dynamics.

Authors:  Sakshi Gupta; Neha Tiwari; Jyoti Verma; Mohd Waseem; Naidu Subbarao; Manoj Munde
Journal:  RSC Adv       Date:  2020-05-27       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.